E-LIB Suche - Ergebnisse für: Shimose, Takayuki

1

Rationale and design of phase II clinical trial of dual inh..:

Kawachi, Hayato ; Yamada, Tadaaki ; Yoshimura, Akihiro...
Therapeutic Advances in Medical Oncology. 15 (2023) - p. , 2023

Link: https://doi.org/10.1177/..

2

A Phase II Trial on Osimertinib as a First-Line Treatment f..:

Chihara, Yusuke ; Takeda, Takayuki ; Goto, Yasuhiro...
The Oncologist. 27 (2022) 11 - p. 903-e834 , 2022

Link: https://doi.org/10.1093/..

3

Phase II study of durvalumab (MEDI 4736) plus carboplatin a..:

Ishii, Hidenobu ; Azuma, Koichi ; Shimose, Takayuki...
Thoracic Cancer. 14 (2022) 1 - p. 105-107 , 2022

Link: https://doi.org/10.1111/..

4

Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Ch..:

Shiraishi, Yoshimasa ; Shimose, Takayuki ; Tsuchiya-Kawano, Yuko...
Cancer Management and Research. 14 (2022) - p. 3449-3453 , 2022

Link: https://doi.org/10.2147/..

5

Effects of pericapsular soft tissue and realignment exercis..:

Hayashi, Kazuo ; Tsunoda, Toshiharu ; Tobo, Yuki..
Current Medical Research and Opinion. 38 (2022) 9 - p. 1567-1578 , 2022

Link: https://doi.org/10.1080/..

6

Phase II study of carboplatin/nab-paclitaxel/atezolizumab c..:

Shiraishi, Yoshimasa ; Kishimoto, Junji ; Shimose, Takayuki...
BMC Cancer. 22 (2022) 1 - p. , 2022

Link: https://doi.org/10.1186/..

7

Erlotinib for Non-Small Cell Lung Cancer with Leptomeningea..:

Nosaki, Kaname ; Yamanaka, Takeharu ; Hamada, Akinobu...
The Oncologist. 25 (2020) 12 - p. e1869-e1878 , 2020

Link: https://doi.org/10.1634/..

8

A phase I/II study of S-1 and irinotecan (IRIS) combined wi..:

Samura, Hironori ; Oki, Eiji ; Okumura, Hiroshi...
Cancer Chemotherapy and Pharmacology. 86 (2020) 2 - p. 285-294 , 2020

Link: https://doi.org/10.1007/..

9

Cessation of nilotinib in patients with chronic myelogenous..:

Nagafuji, Koji ; Matsumura, Itaru ; Shimose, Takayuki...
International Journal of Hematology. 110 (2019) 6 - p. 675-682 , 2019

Link: https://doi.org/10.1007/..

10

Skeletal muscle loss during systemic chemotherapy for color..:

Sasaki, Shun ; Oki, Eiji ; Saeki, Hiroshi...
International Journal of Clinical Oncology. 24 (2019) 10 - p. 1204-1213 , 2019

Link: https://doi.org/10.1007/..

11

Survival Analysis for Patients with ALK Rearrangement-Posit..:

Iwama, Eiji ; Goto, Yasushi ; Murakami, Haruyasu...
The Oncologist. 25 (2019) 4 - p. 306-e618 , 2019

Link: https://doi.org/10.1634/..

12

Longitudinal monitoring of somatic genetic alterations in c..:

Iwama, Eiji ; Sakai, Kazuko ; Hidaka, Noriko...
Cancer. 126 (2019) 1 - p. 219-227 , 2019

Link: https://doi.org/10.1002/..

13

Comparison of computed tomography imaging analyses for eval..:

Hirose, Kosuke ; Oki, Eiji ; Shimose, Takayuki...
International Journal of Clinical Oncology. 24 (2019) 11 - p. 1397-1405 , 2019

Link: https://doi.org/10.1007/..

14

Efficacy and safety of switching to nilotinib in patients w..:

Ishikawa, Jun ; Matsumura, Itaru ; Kawaguchi, Tatsuya...
International Journal of Hematology. 107 (2018) 5 - p. 535-540 , 2018

Link: https://doi.org/10.1007/..

15

Exploration of resistance mechanisms for epidermal growth f..:

Iwama, Eiji ; Sakai, Kazuko ; Azuma, Koichi...
Cancer Science. 109 (2018) 12 - p. 3921-3933 , 2018

Link: https://doi.org/10.1111/..